Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma

Fig. 4

Forest Plot of subgroup analysis for ORR in ITT at stage 2. Response rates were assessed by IRC (a) and investigator (b). ORR objective response rate, ITT intent-to-treatment, CI confidence interval, POD24 progression of disease within 24 months, IRC independent review committee, ECOG PS Eastern Cooperative Oncology Group Performance Score, FLIPI-2 Follicular Lymphoma International Prognostic Index 2

Back to article page